Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101

Abbvie Inc (NYSE:ABBV) and Alpine Immune Sciences Inc. (NASDAQ:ALPN) have announced an exclusive global license and option agreement for Alpine’s best in class dual ICOS/CD28 costimulation antagonist, ALPN-101. AbbVie to co-develop ALPN-101 with Alpine ICOS and CD28 are important costimulatory molecules playing critical roles in inflammatory autoimmune diseases. Alpine’s ALPN-101 is a potent ICOS and […]

AbbVie Inc (NYSE:ABBV) Expresses Confidence In Humira’s Defense Strategy On The International Scale

AbbVie Inc (NYSE:ABBV) AbbVie understands that its business performance is closely linked and even dependent on what happens as Humira. There are reports that Humira is experiencing some existential threats and that is considering the different moves by a large number of US copycats. AbbVie says that there is still hope left as it cites […]

Abbvie Inc (NYSE:ABBV) Quickens Stake Buybacks Following Pharmacyclics, Inc. (NASDAQ:PCYC) Deal

On Wednesday, AbbVie Inc (NYSE:ABBV) announced that it would reacquire shares after the acquisition of Pharmacyclics, Inc. (NASDAQ:PCYC) was finalized. The company announced its plans to buy back stock worth $5 billion from Morgan Stanley. The announcement was made as soon as the acquisition was completed. The news that AbbVie had plans to acquire Pharmacyclics […]

Bristol-Myers Squibb Co (NYSE:BMY), AbbVie Inc (NYSE:ABBV) Developing Drug To Delay Growth of Myeloma Cancer

Bristol-Myers Squibb Co (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) are working in collaboration for a cancer therapy that can delay the progression of the myeloma cancer in less than five months. The company is currently in the final stages of the study and is now looking forward to seeking the approval from the U.S. Food and […]

Galapagos NV (ADR) (NASDAQ:GLPG) Raises IPO Stakes And Gets Positive Response

Galapagos NV (ADR) (NASDAQ:GLPG) has raised the initial public offering (IPO) stake of around $290 or €258 million, and the results seem to have been positive. The first trading day at Nasdaq helped the shares grow by 20.10%. According to the company Founder and CEO Onno van de Stolpe was very happy to be on […]

AbbVie Inc (NYSE:ABBV) Gets Breakthrough For Venetoclax (ABT-199)

In a fast paced world, AbbVie Inc (NYSE:ABBV) intends to take quick actions to make everything falls in line. Recently it mentioned Venetoclax (ABT-199), late stage cancer drug of the company as a strong reason due to which it wanted to acquire Imbruvica-maker Pharmacyclics for a whopping $21 billion. AbbVie anticipates that if blood cancer […]

The U.S. FDA Granted Priority Review To AbbVie Inc (NYSE:ABBV) Hepatitis C Drug

The U.S. FDA granted priority review status to AbbVie Inc (NYSE:ABBV)’s hepatitis C drug to treat adult patients suffering with chronic genotype 4 hepatitis C. It is a key achievement for the company as competition among developers of hepatitis drugs intensifies. The new status reduces the regulatory review period to just six months. The treatment […]

AbbVie Inc. (NYSE:ABBV) May Withdraw Back From the Acquisition Of Shire Plc. (ADR) (NASDAQ:SHPG)

Boston, MA 10/16/2014 (wallstreetpr) – The drug maker Shire Plc. (ADR) (NASDAQ:SHPG) has lost about one-third of its market share in a trading at New York Exchange on Wednesday. The reason of the fall was news that AbbVie Inc. (NYSE:ABBV) who was about to acquire Shire may step back from this deal of acquisition worth […]

Is AbbVie Inc (NYSE:ABBV) Move To Merge With Shire PLC (ADR) (NASDAQ:SHPG) Falling apart?

Boston, MA 10/15/2014 (wallstreetpr) – AbbVie Inc (NYSE:ABBV) move to merge with the Britain-based Shire PLC (ADR) (NASDAQ:SHPG) is showing signs of falling apart. The principal reason for forming such an opinion is undoubtedly the latest tax inversion that was cracked down by the establishment. While AbbVie is dithering and considering the option of scrapping […]

AbbVie Inc. (NYSE:ABBV) $1.6 Billion Shire PLC (ADR) (NASDAQ:SHPG) Break-Up Fee Dilemma

Boston, MA 10/15/2014 (wallstreetpr) –  Proposals intended to make it difficult for American companies to shift their bases out of the U.S have reportedly forced AbbVie Inc. (NYSE:ABBV) to rethink its $55 billion takeover of Shire PLC (ADR) (NASDAQ:SHPG). AbbVie just like other companies is seeking to shift its base to Europe where tax rates are […]

AbbVie Inc (NYSE:ABBV)’s HUMIRA® Approved As First Self-Administering Treatment For Crohn’s Disease In Children

Boston, MA 09/26/2014 (wallstreetpr) – AbbVie Inc (NYSE:ABBV)’s drug HUMIRA® (adalimumab) has gained authorization from the U.S. Food and Drug Administration to treat children suffering from Crohn’s disease if they fail to show significant improvements from currently available treatment means. Alternative Treatment According to PR Newswire news, the company announced its latest achievement with HUMIRA […]

AbbVie Inc (NYSE:ABBV) and Abbott Laboratories (NYSE:ABT) Win Claims Over Dismissal of AndroGel and Humira

Boston, MA 09/26/2014 (wallstreetpr) – After a long fight AbbVie Inc (NYSE:ABBV) and Abbott Laboratories (NYSE:ABT) have finally won their claims against the dismissal of AndroGel testosterone drug and Humira arthritis drug. There was a lawsuit filed against both of these companies that accused that the above mentioned two drugs caused health plans to pay […]

Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors

Boston, MA 09/24/2014 (wallstreetpr) – Celgene Corporation (NASDAQ:CELG) could upset companies like AbbVie Inc (NYSE:ABBV), Amgen, Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE), which are currently minting hefty money through their psoriasis injections currently selling in the market. Celgene Corporation (NASDAQ:CELG) reported on Tuesday that it has received the approval from the Food and Drug Administration for […]

AbbVie Inc (NYSE:ABBV) To Make Several Presentations Proposing New Drugs For Cancer And Tumor Therapies

Boston, MA 09/23/2014 (wallstreetpr) – AbbVie Inc (NYSE:ABBV) announced that will be presenting findings from new researches at the annual meeting of the European Society of Medical Oncology. As mentioned in the PR Newswire article, the conference will be held from Sept 26 through Sept 30, 2014 in Madrid, Spain. AbbVie Inc (NYSE:ABBV) has been […]

AbbVie Inc (NYSE:ABBV) Faces Pension Fund Wrath On Its Merger Deal With Shire PLC (ADR) (NASDAQ:SHPG)

Boston, MA 09/18/2014 (wallstreetpr) – Research-based pharmaceutical company, AbbVie Inc (NYSE:ABBV) is facing the wrath of a pension fund in the U.S. since its merger with Shire PLC (ADR) (NASDAQ:SHPG) sought to shift its residential base to the United Kingdom. The Louisiana pension fund dragged the U.S. company to the court and charged them of […]